Completed

A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

docetaxel

Drug
Who is being recruted

Urogenital Diseases+49

+ Urinary Bladder Diseases

+ Breast Diseases

Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: September 1998
See protocol details

Summary

Principal SponsorAlliance for Clinical Trials in Oncology
Last updated: July 14, 2016
Sourced from a government-validated database.Claim as a partner

Study start date: September 1, 1998

Actual date on which the first participant was enrolled.

OBJECTIVES: Compare the population pharmacokinetics of docetaxel in Caucasians and African American patients with solid tumors. Compare the pharmacodynamic effect of a single dose of docetaxel in relation to hematological toxicity in these patient populations. Determine the CYP3A4 genotype and P-glycoprotein (P-gp) expression and their relationship to docetaxel clearance in these patient populations. OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Patients may receive additional courses beginning 21 days after the first docetaxel dose at the discretion of the physician.

NCT00003565
Principal SponsorAlliance for Clinical Trials in Oncology
Last updated: July 14, 2016
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

109 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesUrinary Bladder DiseasesBreast DiseasesBronchial NeoplasmsCarcinomaCarcinoma, BronchogenicCarcinoma, Squamous CellCranial Nerve DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsLung DiseasesStomatognathic DiseasesMouth DiseasesMouth NeoplasmsNasopharyngeal DiseasesNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Germ Cell and EmbryonalNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueNervous System DiseasesNeuroblastomaOtorhinolaryngologic DiseasesOtorhinolaryngologic NeoplasmsPharyngeal DiseasesPharyngeal NeoplasmsRespiratory Tract DiseasesRespiratory Tract NeoplasmsSalivary Gland DiseasesSkin DiseasesThoracic NeoplasmsUrogenital NeoplasmsUrologic DiseasesUrologic NeoplasmsSkin and Connective Tissue DiseasesNeuroectodermal TumorsNeuroectodermal Tumors, Primitive, PeripheralNeuroectodermal Tumors, PrimitiveNeoplasms, NeuroepithelialOlfactory Nerve DiseasesFemale Urogenital DiseasesMale Urogenital DiseasesSquamous Cell Carcinoma of Head and NeckUrinary Bladder NeoplasmsBreast NeoplasmsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsLung NeoplasmsNasopharyngeal NeoplasmsSalivary Gland NeoplasmsEsthesioneuroblastoma, OlfactorySmall Cell Lung Carcinoma

Criteria

DISEASE CHARACTERISTICS: Histologically proven unresectable solid tumors (e.g., lung, breast, head and neck, bladder) Clinically suitable for treatment with single agent docetaxel Caucasian (at least 2 generations originating in any of the original peoples of Europe, North Africa, or the Middle East) OR African American (at least 2 generations originating in any of the black racial groups of Africa) PATIENT CHARACTERISTICS: Age: 18 and over Performance status: 0-2 Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than upper limit of normal (ULN) AST no greater than 1.5 times ULN AND Alkaline phosphatase no greater than 2.5 times ULN Renal: BUN no greater than 1.5 times ULN Creatinine no greater 1.5 times ULN Other: Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow transplantation Chemotherapy: No prior docetaxel Prior paclitaxel allowed 1 or 2 prior chemotherapy regimens allowed At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) No other concurrent chemotherapy Endocrine therapy: No concurrent hormones for disease related conditions Concurrent steroids for adrenal failure allowed Radiotherapy: At least 2 weeks since prior radiotherapy Palliative radiotherapy allowed except whole brain irradiation for CNS disease Surgery: Not specified Other: At least 48 hours since prior or concurrent ethanol (CYP3A enzyme inducer) or grapefruit juice (CYP3A enzyme inhibitor) At least 7 days since prior or concurrent CYP450 inducing drugs: Antiseizure medications: phenobarbital, phenytoin, carbamazepine, or lamotrigine Anti-TB therapy: rifampin, isoniazid, or sulfinpyrazone At least 7 days since prior or concurrent CYP450 3A inhibiting drugs: Macrolides: erythromycin, clarithromycin, azithromycin, or roxithromycin Azoles: ketoconazole, fluconazole, or itraconazole Other antibiotics: metronidazole or chloramphenicol Anti-HIV drugs: ritonavir, indinavir, nelfinavir, or delavirdine Immunosuppressive agents: cyclosporine Antidepressant agent: nefazodone

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Patients may receive additional courses beginning 21 days after the first docetaxel dose at the discretion of the physician.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 74 locations

Northeast Alabama Regional Medical Center

Anniston, United StatesOpen Northeast Alabama Regional Medical Center in Google Maps

Rebecca and John Moores UCSD Cancer Center

La Jolla, United States

Veterans Affairs Medical Center - San Diego

San Diego, United States

UCSF Comprehensive Cancer Center

San Francisco, United States
Completed74 Study Centers